Cellmid Ltd - Independent test results for the Wondfo SARS-COV-2 Test
Cellmid Ltd (ASX:CDY)

Independent test results for the Wondfo SARS-COV-2 Test

Published Apr 22, 2020

What happened?


What's happened?

Cellmid Limited (ASX:CDY) has announced that a validation study has been completed for the Wondfo SARS-COV-2 test, which Cellmid had previously signed a supply agreement for (supply agreement was announced on the 27th March 2020).

What are the key highlights?

  1. Wondfo’s SARS-VoC-2 diagnostic was tested by The National Institute of Virology of the Indian Council of Medical Research.
  2. Wondfo’s test detected antibodies as early as day 3 from COVID-19 symptoms.
  3. 100% of samples (14) from day 6 of disease onset tested positive for antibodies.
  4. There was no cross reactivity (false positives) detected.
  5. Results are consistent with Wondfo’s study of 596 COVID-19 patient samples.
  6. The validation study was conducted on 24 individual samples of COVID-19 patients from day 2 to day 13 from the onset of symptoms, following confirmation of viral load using nucleotide testing.
  7. The Cellmid sponsored Wondfo SARS-CoV-2kit is manufactured to the highest standards in a facility certified by the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA) and the Chinese National Medical Products Administration (NMPA) under the Medical Device Single Audit Program (MDSAP).

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Cellmid share placement raises $6m to fund SARS-V-2 diagnostic test roll out
What's happened? Cellmid Limited (ASX:CDY) has raised $6 million (before costs) via a share placement from institutional...
3 years ago
Cellmid enter into supply agreement for COVID-19 rapid diagnostic test
What's happened? Cellmid Ltd (ASX: CDY, “Cellmid”) have announced that it has entered into a supply agreement for a COVI...
3 years ago
Cellmid Ltd (ASX:CDY) reports increase in sales & 18 new distribution channels in 1H FY2020 results
What's happened? Cellmid Limited (ASX:CDY, "Cellmid") released its financial results for 1H FY2020. What are t...
4 years ago
Around the web
Closing Bell: ASX down on Beijing tantrum, biotech proves Sandy Beard no rash decision
The S&P/ASX200 is lower in late trade on Tuesday, dropping around 30 points or 0.4%, after iron...
via stockhead.com.au
7 startup founders share the lessons they learned in 2021 that they’ll be applying to the year ahead
2021 didn’t quite turn out way we’d hoped after the initial pandemic chaos on 2020. With the past 12...
via startupdaily.net
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
via stockhead.com.au
Powered by  
  • Company
    Cellmid Ltd
  • Website
  • Sector
    Biotechnology
  • Industry
    Biotechnology
  • Code
    ASX:CDY
  • Socials
View Cellmid Ltd's Profile

How do I invest?

Considering investing in Cellmid Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:CDY

    On your online investment platform search for the stock ticker code ASX:CDY to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up